AstraZeneca (LON:AZN) had its price objective hoisted by Deutsche Bank from GBX 6,800 ($88.85) to GBX 6,900 ($90.16) in a report released on Monday morning, Borsen Zeitung reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.
Several other research firms also recently commented on AZN. HSBC downgraded shares of easyJet to a hold rating in a report on Tuesday, April 2nd. Kepler Capital Markets set a €11.00 ($12.79) price objective on shares of E.On and gave the company a buy rating in a report on Monday, May 13th. JPMorgan Chase & Co. downgraded shares of Sogou from a neutral rating to an underweight rating and dropped their price objective for the company from $5.50 to $4.12 in a report on Thursday, June 27th. Goldman Sachs Group raised shares of to a neutral rating and lowered their price target for the company from GBX 1,855 ($24.24) to GBX 1,800 ($23.52) in a report on Thursday, June 27th. Finally, Citigroup set a $13.00 price target on shares of e.l.f. Beauty and gave the company a hold rating in a report on Monday, May 13th. Three investment analysts have rated the stock with a sell rating, six have given a hold rating and ten have given a buy rating to the company. The stock has an average rating of Hold and a consensus target price of GBX 6,502.94 ($84.97).
AZN opened at GBX 6,306 ($82.40) on Monday. The firm’s 50-day moving average is GBX 6,241.74. AstraZeneca has a 52 week low of GBX 5,240 ($68.47) and a 52 week high of GBX 6,634 ($86.68). The company has a market cap of $83.72 billion and a P/E ratio of 33.19. The company has a debt-to-equity ratio of 179.66, a current ratio of 0.75 and a quick ratio of 0.57.
AstraZeneca Company Profile
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Recommended Story: Earnings Per Share
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.